Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Point-of-Care CD4 Test Receives CE Marking

By LabMedica International staff writers
Posted on 21 Jan 2014
CE marking validation for the new test platform opens the way to highly accessible, reliable CD4 T-cell testing for HIV positive patients worldwide. More...


Zyomyx (Fremont, CA, USA) has now received the CE marking for its "MyT4" point-of-care CD4 test, intended to rapidly identify the concentration of CD4 T-lymphocytes in patients with HIV/AIDS and so to assist in decisions for treatment initiation and in drug monitoring. MyT4 is the first of an expanding line of diagnostic tests originating from Zyomyx's portfolio of proprietary platform technologies capable of moving laboratory tests for cells, proteins, and infectious agents to the point-of-care (POC) and thereby providing immediate benefits to clinicians and patients in multiple disease areas.

Zyomyx, a vertically integrated diagnostics company, developed the MyT4 test, secured its CE marking, and it expects to begin selling the product in 2014 in collaboration with Mylan, Inc. (Canonsburg, PA, USA) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). As a POC solution, this quantitative test provides fast time-to-result—within minutes—and will be the only service-free test on the market, as it does not require maintenance or complex instrumentation.

"We are delighted to have met this regulatory milestone for MyT4," said Peter Wagner, President and CEO of Zyomyx; "The Zyomyx test is the fastest CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. Zyomyx will continue to dedicate its efforts to bringing next-generation point-of-care diagnostic solutions to the market."

MyT4 is well configured to meet the needs of developing countries. For the millions of HIV/AIDS patients worldwide receiving or in need of antiretroviral therapy, a major barrier to initiating and monitoring treatment for patients is the lack of access to routine CD4 testing because flow cytometers are expensive, complex, and are only available in centralized locations, often requiring patients to wait weeks to obtain a result. Zyomyx's test will enable millions of HIV+ people to quickly receive reliable CD4 results and start or monitor lifesaving antiretroviral treatment without delay.

Related Links:

Zyomyx



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.